What is B. Riley’s Estimate for VRDN Q2 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Equities research analysts at B. Riley issued their Q2 2025 earnings estimates for Viridian Therapeutics in a research note issued on Monday, March 3rd. B. Riley analyst K. Patel expects that the company will earn ($1.14) per share for the quarter. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.24. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%.

Other equities analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price target on shares of Viridian Therapeutics in a research report on Monday, December 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Royal Bank of Canada upped their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 17th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $27.00 price target (down previously from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Finally, TD Cowen initiated coverage on shares of Viridian Therapeutics in a research report on Monday, November 25th. They set a “buy” rating for the company. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $35.70.

Viridian Therapeutics Stock Performance

Shares of VRDN stock opened at $15.23 on Tuesday. Viridian Therapeutics has a one year low of $11.40 and a one year high of $27.20. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The company has a 50 day moving average price of $18.02 and a 200 day moving average price of $19.70. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -3.53 and a beta of 1.32.

Institutional Investors Weigh In On Viridian Therapeutics

Several large investors have recently made changes to their positions in VRDN. Great Point Partners LLC grew its holdings in Viridian Therapeutics by 50.0% during the 3rd quarter. Great Point Partners LLC now owns 750,000 shares of the company’s stock valued at $17,062,000 after purchasing an additional 250,000 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in Viridian Therapeutics during the 3rd quarter valued at $8,917,000. JPMorgan Chase & Co. grew its holdings in Viridian Therapeutics by 218.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company’s stock valued at $9,108,000 after purchasing an additional 274,641 shares in the last quarter. Barclays PLC grew its holdings in Viridian Therapeutics by 113.1% during the 3rd quarter. Barclays PLC now owns 125,397 shares of the company’s stock valued at $2,851,000 after purchasing an additional 66,550 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in Viridian Therapeutics during the 3rd quarter valued at $788,000.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.